Abstract

Recently, biopharmaceutical drugs take a big part in the pharmaceutical market with the development of genetic engineering. Therapeutic antibodies, one of the representative biopharmaceuticals, have strong therapeutic efficacy in various diseases such as autoimmune disease, rheumatism and cancer. Antibodies are widely used as targeted delivery systems, diagnostics and therapeutics because of their high specific recognition ability. In addition, the market for therapeutic antibodies is expanding further with the development of new biologic drugs such as biosimilar and biobetter. In particular, cancer immunotherapy has shown excellent efficacy for the treatment of cancer by regulating the immune response. In recent years, antibody-drug conjugates (ADCs), immune checkpoint inhibitors and therapeutic antibodies have been developed by many researchers and pharmaceutical companies and approved by U.S. food and drug administration as a potential strategy for the treatment of cancer. Although cancer immunotherapy has a strong therapeutic efficacy, there are still limitations to overcome such as for the treatment of solid tumor, immunogenicity and resistance. To solve these problems, new biomarkers, bispecific antibodies and combinatorial therapy with chemotherapy are being investigated. In this review, we describe the mechanism of immune response with respect to antibody therapeutics, characteristics of target cancers and discuss the potentials of cancer immunotherapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.